News from the FDA/CDC

FDA approves premixed, low-volume colon-cleansing solution


 

The Food and Drug Administration has approved a premixed sodium picosulfate, magnesium oxide, and anhydrous citric acid oral solution (Clenpiq) for cleansing of the colon in adults preparing to undergo colonoscopy, according to Ferring Pharmaceuticals.

The sodium picosulfate, magnesium oxide, and anhydrous citric acid oral solution is a relatively low-volume, premixed, cranberry-flavored solution, making it easier to use and more palatable for patients.

Sodium picosulfate, magnesium oxide, and anhydrous citric acid oral solution is approved with two dosing options: split dose, one dose the evening prior and one dose the morning of the procedure, or the day before dose, which involves taking both doses the day prior to the procedure. Day before dosing is an alternative and should be used when split dosing is not appropriate. After each dose of sodium picosulfate, magnesium oxide, and anhydrous citric acid oral solution, clear liquids should be consumed based on the dosing recommendation. The American College of Gastroenterology recommends the split-dose regimen because of its improved cleansing quality of the colon and better tolerability of the liquid volume by patients.

Patients with impaired renal function should exercise caution if using sodium picosulfate, magnesium oxide, and anhydrous citric acid oral solution as it may effect renal function. A more comprehensive list of safety information is available at www.clenpiq.com.

To help your patients understand and prepare for a colonoscopy, use AGA’s patient education materials at http://www.gastro.org/patient-care/procedures/colonoscopy.

Next Article: